慢性髓性白血病伴附加染色体异常疗效及预后的相关性分析OA

Objective To explore the correlation between the diagnosis,treatment,progression and prognosis of chronic myeloid leukemia(CML)in chronic phase(CML-CP)patients with additional chromo-somal abnormalities(ACAs)at the initial diagnosis.Methods The clinical data of 92 patients with newly di-agnosed CML-CP admitted to the hospital from January 1,2016 to December 31,2022 were retrospectively an-alyzed.The clinical and genetic characteristics were analyzed.Kaplan Meier method was used to analyze the differences in survival distribution of CML-CP patients with or without ACAs,and to explore the correlation between CML-CP patients with ACAs and disease diagnosis,treatment,and prognosis.Results BCR-ABL1 fusion gene was detected in the initial bone marrow images of 92 CML-CP patients(100%positive rate),with 82 cases(89.13%)in the pure t(9;22)group and 10 cases(10.87%)in the ACAs group.The survival time of CML-CP patients was 78.49-87.64 months,with a median of 83.06 months.Compared with simple t(9;22),the onset age and overall survival time of ACAs patients were lower,and they had a higher risk of infection,and the differences were statistically significant(P<0.05).ACAs were independent risk factors for poor prognosis in CML-CP patients.Conclusion ACAs may be one of the factors leading to the progression and poor prognosis of CML.